[{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idera Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Aceragen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Acquisition","leadProduct":"Sodium Fusidate","moa":"||Elongation factor G","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idera Pharmaceuticals \/ Idera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Idera Pharmaceuticals"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"ABBV-368","moa":"monoclonal antibodies: immunomodulating","graph1":"Oncology","graph2":"Phase I","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Idera Pharmaceuticals \/ Idera Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Idera Pharmaceuticals \/ Idera Pharmaceuticals"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"IMO-3100","moa":"Toll-like receptor 7 (TLR7)","graph1":"Dermatology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Oligonucleotide","year":"2013","type":"Inapplicable","leadProduct":"IMO-8400","moa":"Toll-like receptor 8 | Toll-like receptor 7 | Toll-like receptor 9","graph1":"Dermatology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"IMO-8400","moa":"Toll-like receptor 8 | Toll-like receptor 7 | Toll-like receptor 9","graph1":"Immunology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"IMO-8400","moa":"Toll-like receptor 8 | Toll-like receptor 7 | Toll-like receptor 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2015","type":"Inapplicable","leadProduct":"IMO-8400","moa":"Toll-like receptor 8 | Toll-like receptor 7 | Toll-like receptor 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"IMO-8400","moa":"Toll-like receptor 8 | Toll-like receptor 7 | Toll-like receptor 9","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2016","type":"Inapplicable","leadProduct":"IMO-2125","moa":"Toll-like receptor 9","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2017","type":"Inapplicable","leadProduct":"IMO-2125","moa":"Toll-like receptor 9","graph1":"Oncology","graph2":"Phase I","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"Tilsotolimod","moa":"Toll-like receptor 9","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"||Toll-like receptor 9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like receptor 9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like receptor 9","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like receptor 9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Bristol Myers Squibb","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like receptor 9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like receptor 9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like receptor 9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"||Toll-like receptor 9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Private Placement","leadProduct":"Ipilimumab","moa":"||Toll-like receptor 9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like receptor 9","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ AbbVie Inc"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Ipilimumab","moa":"||Toll-like receptor 9","graph1":"Oncology","graph2":"Phase III","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Idera Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idera Pharmaceuticals","sponsor":"Idera Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Oligonucleotide","year":"2019","type":"Inapplicable","leadProduct":"Tilsotolimod","moa":"Toll-like receptor 9","graph1":"Oncology","graph2":"Phase II","graph3":"Idera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Idera Pharmaceuticals \/ Idera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Idera Pharmaceuticals \/ Idera Pharmaceuticals"}]
Find Clinical Drug Pipeline Developments & Deals by Idera Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target